Six-month data back Biotronik's absorbable metal stent:
This article was originally published in Clinica
Executive Summary
Six-month follow-up studies from the first human trials of an absorbable metal stent (AMS) developed by Biotronik, have shown the device to be safe and effective when used to treat blocked arteries below the knee. Only one of the 20 stent recipients needed an amputation during the follow-up period, the Berlin, Germany firm said, adding that this was an "excellent" outcome since all the patients were high-risk. Some 79% of each stented vessel remained patent, indicating that the arteries remained stabilised even after the stent had been absorbed, a process that takes between two and three months to complete.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.